The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review

Purpose: Immune checkpoint inhibitor (ICI) use can lead to immune-related adverse events (irAEs) that require treatment with immunosuppressive medications in moderate to severe cases. Oncology society guidelines recommend systemic steroids and immunosuppressants such as infliximab and vedolizumab fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Machado, Antonio Pizuorno, Ratliff, Hunter, Abdelwahab, Ahmed, Vohra, Muhammad H., Kuang, Andrew, Shatila, Malek, Khan, Muhammad Ali, Shafi, Menhaz A., Thomas, Anusha S., Philpott, Jessica, Alhalabi, Omar, Wang, Yinghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583582/
https://www.ncbi.nlm.nih.gov/pubmed/37859810
http://dx.doi.org/10.7150/jca.87335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583582/
https://www.ncbi.nlm.nih.gov/pubmed/37859810
http://dx.doi.org/10.7150/jca.87335

Ejemplares similares